

## Referenzen

- Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T et al: CONSENSUS REPORT: Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-024-06205-5>
- Spix C, Blettner, M. Screening. *Deutsches Ärzteblatt* 2012;21:385-390.
- Wilson, J.M.G.; Jungner, G. Principles and Practice of Screening for Disease. WHO papers No 34. 1968. <https://apps.who.int/iris/handle/10665/37650>
- Grace SL, Cooper A, Jones AG, McDonald TJ. Zinc transporter 8 autoantibody testing requires age-related cut-offs. *BMJ Open Diabetes Res Care*. 2021 Aug;9(1):e002296. doi: 10.1136/bmjdc-2021-002296. PMID: 34348918; PMCID: PMC8340275.
- Lampasona V, Pittman DL, Williams AJ, Achenbach P, Schlosser M, Akolkar B, Winter WE; Participating Laboratories. Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. *Clin Chem*. 2019 Sep;65(9):1141-1152. doi: 10.1373/clinchem.2019.304196. Epub 2019 Aug 13. PMID: 31409598; PMCID: PMC8936135.
- Marzinotto I, Pittman DL, Williams AJK, Long AE, Achenbach P, Schlosser M, Akolkar B, Winter WE, Lampasona V; participating laboratories. Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. *Diabetologia*. 2023 May;66(5):897-912. doi: 10.1007/s00125-023-05877-9. Epub 2023 Feb 10. PMID: 36759347; PMCID: PMC10036445.
- Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson DM, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. *Diabetologia*. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25. PMID: 31768570; PMCID: PMC7229995.
- Simmons KM, Alkanani AK, McDaniel KA, Goynes C, Miao D, Zhao Z, Yu L, Michels AW. Islet Autoantibody Measurements from Dried Blood Spots on Filter Paper Strongly Correlate to Serum Levels. *PLoS One*. 2016 Nov 15;11(11):e0166213. doi: 10.1371/journal.pone.0166213. PMID: 27846247; PMCID: PMC5112938.
- Sims EK, Besser REJ, Dayan C, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. *Diabetes* 2022;71(4):610-623. DOI: 10.2337/dbi20-0054.
- Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. *Pediatr Diabetes* 2022;23(8):1175-1187. DOI: 10.1111/pedi.13410.
- Segeer H, Wurm M, Grimsman JM, et al. Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence—Incidence and Risk Factors. *Dtsch Arztebl Int* 2021;118(22):367-372. DOI: 10.3238/arztebl.m2021.0133.
- Ziegler AG, Kick K, Bonifacio E, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. *JAMA* 2020;323(4):339-351. DOI: 10.1001/jama.2019.21565.
- Hummel S, Carl J, Friedl N, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. *Diabetologia* 2023;66(9):1633-1642. DOI: 10.1007/s00125-023-05953-0.
- Karges B, Prinz N, Placzek K, et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. *Diabetes Care* 2021;44(5):1116-1124. DOI: 10.2337/dc20-1829.
- Steck AK, Larsson HE, Liu X, et al. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. *Pediatr Diabetes* 2017;18(8):794-802. DOI: 10.1111/pedi.12485.
- EMA. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev2 Committee for Medicinal Products for Human Use (CHMP) 2023.
- Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. *Diabetes Care* 2010;33(6):1206-12. DOI: 10.2337/dc09-1040.
- O'Donnell HK, Rasmussen CG, Dong F, et al. Anxiety and Risk Perception in Parents of Children Identified by Population Screening as High Risk for Type 1 Diabetes. *Diabetes Care* 2023;46(12):2155-2161. DOI: 10.2337/dc23-0350.
- Vehik K, Lynch KF, Schatz DA, et al. Reversion of beta-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. *Diabetes Care* 2016;39(9):1535-42. DOI: 10.2337/dc16-0181.
- Holder M, Ehehalt S. Significant reduction of ketoacidosis at diabetes onset in children and adolescents with type 1 diabetes—The Stuttgart Diabetes Awareness Campaign, Germany. *Pediatr Diabetes* 2020;21(7):1227-1231. DOI: 10.1111/pedi.13064.
- Maio G. *Mittelpunkt Mensch. Prädiktive Gendiagnostik.*: Schattauer 2017.
- Karges B. Pro & Kontra Freiwilliges Screening auf Typ 1 Diabetes. *Deutsches Ärzteblatt* 2023;35-36:A1421.
- Karges B, Schwandt A, Heidtmann B, et al. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. *JAMA* 2017;318(14):1358-1366. DOI: 10.1001/jama.2017.13994.
- Karges B, Tittel SR, Bey A, et al. Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study. *Lancet Diabetes Endocrinol* 2023;11(5):314-323. DOI: 10.1016/S2213-8587(23)00061-X.
- Johnson SB, Smith LB. General Population Screening for Islet Autoantibodies: Psychosocial Challenges. *Diabetes Care* 2023;46(12):2123-2125. DOI: 10.2337/dci23-0061.